Pictet Asset Management
TBPH icon

Pictet Asset Management’s Theravance Biopharma TBPH Stock Holding History

Pictet Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-684,892
Closed -$5.55M – 2081
2024
Q3 		$5.55M Sell
684,892
-193,763
-22% -$1.68M 0.01% 782
2024
Q2 		$7.45M Sell
878,655
-1,164,956
-57% -$10.5M 0.01% 699
2024
Q1 		$18.4M Sell
2,043,611
-124,786
-6% -$1.16M 0.02% 508
2023
Q4 		$24.4M Buy
2,168,397
+160,144
+8% +$1.61M 0.03% 431
2023
Q3 		$17.3M Buy
+2,008,253
New +$19.4M 0.02% 492

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Pictet Asset Management's TBPH Position: Q4 2024 in Review

Pictet Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2024, closing a stake of 684,892 shares — an estimated $5.55M sold.

Pictet Asset Management first reported a position in TBPH in Q3 2023 and held it in 5 quarters. The position peaked at $24.4M in Q4 2023. 128 funds tracked by Wall St. Rank hold TBPH as of Q4 2024.

  • Pictet Asset Management reported no remaining Theravance Biopharma position as of Q4 2024 after selling out during the quarter.
  • Pictet Asset Management sold 684,892 Theravance Biopharma shares in Q4 2024, an estimated $5.55M.
  • Pictet Asset Management first reported a position in Theravance Biopharma in Q3 2023 and held it in 5 quarters.
  • Pictet Asset Management's Theravance Biopharma position peaked at $24.4M in Q4 2023.
  • 128 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2024.

Based on Pictet Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.